Cala Health, Inc.

Cala Health is a bioelectronic medicine company specializing in wearable neuromodulation therapies for chronic diseases. Founded in 2014 as a Stanford University spinout, Cala develops non-invasive peripheral nerve stimulation devices using transcutaneous afferent patterned stimulation (TAPS). The company's flagship product, the Cala kIQ, is an FDA-cleared wrist-worn device for reducing action hand tremor in essential tremor and Parkinson's disease patients. The Cala kIQ delivers on-demand TAPS therapy with clinically proven efficacy—patients report tremor reduction within 40 minutes, with relief lasting over 90 minutes post-session. The company supports a comprehensive patient lifecycle ecosystem including prescription fulfillment, insurance reimbursement assistance, connected care services via MyCala.com patient portal, telemedicine consultation, and medication management support. Medicare and VA coverage are available for qualifying beneficiaries. Cala Health is expanding its therapeutic focus to neurology, cardiology, and psychiatry applications.